Literature DB >> 6206904

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias.

A Pinto, V Attadia, A Fusco, F Ferrara, O A Spada, P P Di Fiore.   

Abstract

In this study, the effects of 5-aza-2'-deoxycytidine on differentiation of human leukemic cells in primary suspension culture are reported for the first time. Morphological and functional differentiation was induced in cells from two acute monoblastic leukemias and two of three acute myeloid leukemias following repeated exposures to 1 mumol/L 5-aza-2'-deoxycytidine. The observation that nontoxic concentrations of the drug are able to induce the in vitro differentiation of both monoblastic and myeloblastic leukemic cells into mature elements may encourage the exploitation of the differentiating properties of 5-aza-2'-deoxycytidine in chemotherapy protocols for acute non-lymphoblastic leukemias.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206904

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

Authors:  G Schwartsmann; H Schunemann; C N Gorini; A F Filho; C Garbino; G Sabini; I Muse; L DiLeone; D R Mans
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.

Authors:  Zhenbo Hu; Soledad Negrotto; Xiaorong Gu; Reda Mahfouz; Kwok Peng Ng; Quteba Ebrahem; Edward Copelan; Harinder Singh; Jaroslaw P Maciejewski; Yogen Saunthararajah
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 4.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

5.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

6.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

Review 7.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

8.  Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine.

Authors:  Bao-Zhu Yuan; Amy M Jefferson; Nicholas C Popescu; Steven H Reynolds
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

9.  The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.

Authors:  Benedetta Costantini; Shahram Y Kordasti; Austin G Kulasekararaj; Jie Jiang; Thomas Seidl; Pilar Perez Abellan; Azim Mohamedali; Nicolas Shaun B Thomas; Farzin Farzaneh; Ghulam J Mufti
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 10.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.